L. Galli

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Outcomes of second‐line antiretroviral therapy among children living with HIV: a global cohort analysis

M. Yotebieng, C. Giaquinto, L. Mofenson, 2020, Journal of the International AIDS Society.

Osteoprotegerin and bone turnover markers in heavily pretreated HIV‐infected patients

E. Seminari, A. Lazzarin, F. Dorigatti, 2005, HIV medicine.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Number of daily pills, dosing schedule, self‐reported adherence and health status in 2010: a large cross‐sectional study of HIV‐infected patients on antiretroviral therapy

A. Lazzarin, A. Castagna, N. Gianotti, 2013, HIV Medicine.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

Sismes IX National Congress

P. Cinque, G. Merati, G. Pavei, 2017, Sport Sciences for Health.

Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort)

A. Bartoloni, A. Pignone, D. Tacconi, 2023, Viruses.